Lipson, Evan J.

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine

Cancer Genomics and DiagnosticsPrenatal Screening and Diagnostics

Cited by 5,067

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 2,222

PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma

Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine

Polyomavirus and related diseasesCancer Immunotherapy and Biomarkers

Cited by 1,258

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J. (2016) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersChemotherapy-induced cardiotoxicity and mitigation

Cited by 511

Cardiovascular toxicities associated with immune checkpoint inhibitors

Hu, J.-R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., Lyon, A. R., Padera, R. F., Johnson, D. B., & Moslehi, J. (2019) · Cardiovascular Research

Cancer Immunotherapy and BiomarkersChemotherapy-induced cardiotoxicity and mitigation

Cited by 508

Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy

Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., et al. (2019) · Journal of Clinical Oncology

Polyomavirus and related diseasesNonmelanoma Skin Cancer Studies

Cited by 396

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

Braaten, T. J., Brahmer, J. R., Forde, P. M., Le, D., Lipson, E. J., Naidoo, J., Schollenberger, M., Zheng, L., Bingham, C. O., Shah, A. A., et al. (2020) · Annals of the Rheumatic Diseases

Cancer Immunotherapy and BiomarkersRheumatoid Arthritis Research and Therapies

Cited by 230

Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade

Stein, J. E., Lipson, E. J., Cottrell, T. R., Forde, P. M., Anders, R. A., Cimino-Mathews, A., Thompson, E. D., Allaf, M. E., Yarchoan, M., Feliciano, J., et al. (2020) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 177

Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity

Liu, C., Somasundaram, A., Manne, S., Gocher, A. M., Szymczak-Workman, A. L., Vignali, K. M., Scott, E. N., Normolle, D. P., John Wherry, E., Lipson, E. J., et al. (2020) · Nature Immunology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 151

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

Lipson, E. J., Tawbi, H. A.-H., Schadendorf, D., Ascierto, P. A., Matamala, L., Gutiérrez, E. C., Rutkowski, P., Gogas, H., Lao, C. D., Janoski de Menezes, J., et al. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 150

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation

Morales, R. E., Shoushtari, A. N., Walsh, M. M., Grewal, P., Lipson, E. J., & Carvajal, R. D. (2015) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 110

A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors

Shaikh, F. Y., White, J. R., Gills, J. J., Hakozaki, T., Richard, C., Routy, B., Okuma, Y., Usyk, M., Pandey, A., Weber, J. S., et al. (2021) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 44